XML 55 R42.htm IDEA: XBRL DOCUMENT v3.21.2

Revenue - Business Revenue (Details) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 26, 2021	Jun. 27, 2020	Jun. 26, 2021	Jun. 27, 2020
Disaggregation of Revenue [Line Items]
Revenues	$ 1,168,300,000	$ 822,900,000	$ 4,315,700,000	$ 2,429,500,000
Contract with Customer, Liability, Revenue Recognized	20,100,000	18,000,000.0	100,900,000	95,500,000
United States
Disaggregation of Revenue [Line Items]
Revenues	749,900,000	660,800,000	2,951,700,000	1,868,500,000
International
Disaggregation of Revenue [Line Items]
Revenues	418,400,000	162,100,000	1,364,000,000.0	561,000,000.0
Diagnostics
Disaggregation of Revenue [Line Items]
Revenues	665,500,000	532,200,000	2,858,200,000	1,163,200,000
Diagnostics | United States
Disaggregation of Revenue [Line Items]
Revenues	357,200,000	439,100,000	1,825,800,000	909,100,000
Diagnostics | International
Disaggregation of Revenue [Line Items]
Revenues	308,300,000	93,100,000	1,032,400,000	254,100,000
Diagnostics | Cytology & Perinatal
Disaggregation of Revenue [Line Items]
Revenues	115,900,000	64,100,000	357,900,000	298,700,000
Diagnostics | Cytology & Perinatal | United States
Disaggregation of Revenue [Line Items]
Revenues	73,900,000	40,300,000	230,800,000	191,100,000
Diagnostics | Cytology & Perinatal | International
Disaggregation of Revenue [Line Items]
Revenues	42,000,000.0	23,800,000	127,100,000	107,600,000
Diagnostics | Molecular Diagnostics
Disaggregation of Revenue [Line Items]
Revenues	536,400,000	460,300,000	2,467,000,000.0	829,500,000
Diagnostics | Molecular Diagnostics | United States
Disaggregation of Revenue [Line Items]
Revenues	270,100,000	391,000,000.0	1,561,700,000	683,000,000.0
Diagnostics | Molecular Diagnostics | International
Disaggregation of Revenue [Line Items]
Revenues	266,300,000	69,300,000	905,300,000	146,500,000
Diagnostics | Blood Screening
Disaggregation of Revenue [Line Items]
Revenues	13,200,000	7,800,000	33,300,000	35,000,000.0
Diagnostics | Blood Screening | United States
Disaggregation of Revenue [Line Items]
Revenues	13,200,000	7,800,000	33,300,000	35,000,000.0
Diagnostics | Blood Screening | International
Disaggregation of Revenue [Line Items]
Revenues	0	0	0	0
Breast Health
Disaggregation of Revenue [Line Items]
Revenues	349,000,000.0	224,000,000.0	1,018,000,000.0	862,800,000
Breast Health | United States
Disaggregation of Revenue [Line Items]
Revenues	273,200,000	170,600,000	784,400,000	661,500,000
Breast Health | International
Disaggregation of Revenue [Line Items]
Revenues	75,800,000	53,400,000	233,600,000	201,300,000
Breast Health | Breast Imaging
Disaggregation of Revenue [Line Items]
Revenues	280,300,000	193,200,000	817,800,000	718,200,000
Breast Health | Breast Imaging | United States
Disaggregation of Revenue [Line Items]
Revenues	218,400,000	145,600,000	619,500,000	541,100,000
Breast Health | Breast Imaging | International
Disaggregation of Revenue [Line Items]
Revenues	61,900,000	47,600,000	198,300,000	177,100,000
Breast Health | Interventional Breast Solutions
Disaggregation of Revenue [Line Items]
Revenues	68,700,000	30,800,000	200,200,000	144,600,000
Breast Health | Interventional Breast Solutions | United States
Disaggregation of Revenue [Line Items]
Revenues	54,800,000	25,000,000.0	164,900,000	120,400,000
Breast Health | Interventional Breast Solutions | International
Disaggregation of Revenue [Line Items]
Revenues	13,900,000	5,800,000	35,300,000	24,200,000
GYN Surgical
Disaggregation of Revenue [Line Items]
Revenues	127,900,000	51,500,000	366,200,000	275,900,000
GYN Surgical | United States
Disaggregation of Revenue [Line Items]
Revenues	103,900,000	42,100,000	296,800,000	227,600,000
GYN Surgical | International
Disaggregation of Revenue [Line Items]
Revenues	24,000,000.0	9,400,000	69,400,000	48,300,000
Medical Aesthetics
Disaggregation of Revenue [Line Items]
Revenues	0	0	0	65,300,000
Medical Aesthetics | United States
Disaggregation of Revenue [Line Items]
Revenues			0	30,900,000
Medical Aesthetics | International
Disaggregation of Revenue [Line Items]
Revenues			0	34,400,000
Skeletal Health
Disaggregation of Revenue [Line Items]
Revenues	25,900,000	15,200,000	73,300,000	62,300,000
Skeletal Health | United States
Disaggregation of Revenue [Line Items]
Revenues	15,600,000	9,000,000.0	44,700,000	39,400,000
Skeletal Health | International
Disaggregation of Revenue [Line Items]
Revenues	$ 10,300,000	$ 6,200,000	$ 28,600,000	$ 22,900,000

X

- Definition

Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045

+ Details

Name:	us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

+ Details

Name:	us-gaap_Revenues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Details

Name:	srt_StatementGeographicalAxis=country_US
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_StatementGeographicalAxis=holx_InternationalMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_StatementBusinessSegmentsAxis=holx_DiagnosticsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=holx_CytologyPerinatalMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=holx_MolecularDiagnosticsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=holx_BloodScreeningMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_StatementBusinessSegmentsAxis=holx_BreastHealthMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=holx_BreastImagingMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=holx_InterventionalBreastSolutionsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_StatementBusinessSegmentsAxis=holx_GynSurgicalMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_StatementBusinessSegmentsAxis=holx_MedicalAestheticsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_StatementBusinessSegmentsAxis=holx_SkeletalHealthMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: